JP2011500598A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011500598A5 JP2011500598A5 JP2010529091A JP2010529091A JP2011500598A5 JP 2011500598 A5 JP2011500598 A5 JP 2011500598A5 JP 2010529091 A JP2010529091 A JP 2010529091A JP 2010529091 A JP2010529091 A JP 2010529091A JP 2011500598 A5 JP2011500598 A5 JP 2011500598A5
- Authority
- JP
- Japan
- Prior art keywords
- pain
- ring
- aliphatic
- cor
- membered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002193 Pain Diseases 0.000 claims description 64
- 150000001875 compounds Chemical class 0.000 claims description 37
- 125000001931 aliphatic group Chemical group 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 30
- 239000001257 hydrogen Substances 0.000 claims description 30
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 25
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 20
- 125000003118 aryl group Chemical group 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 20
- 150000002367 halogens Chemical class 0.000 claims description 20
- 230000001154 acute effect Effects 0.000 claims description 19
- 229910052717 sulfur Chemical group 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 15
- 125000005842 heteroatom Chemical group 0.000 claims description 14
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 239000011593 sulfur Chemical group 0.000 claims description 14
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 14
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 13
- 208000004296 neuralgia Diseases 0.000 claims description 13
- 239000001301 oxygen Chemical group 0.000 claims description 13
- 208000008035 Back Pain Diseases 0.000 claims description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 12
- 230000001684 chronic effect Effects 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 125000002950 monocyclic group Chemical group 0.000 claims description 11
- 125000004043 oxo group Chemical group O=* 0.000 claims description 10
- 208000021722 neuropathic pain Diseases 0.000 claims description 9
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 9
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 8
- 125000004429 atom Chemical group 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 229920006395 saturated elastomer Polymers 0.000 claims description 8
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 7
- 206010019233 Headaches Diseases 0.000 claims description 6
- 208000005615 Interstitial Cystitis Diseases 0.000 claims description 6
- 208000019695 Migraine disease Diseases 0.000 claims description 6
- 206010028836 Neck pain Diseases 0.000 claims description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 231100000869 headache Toxicity 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 206010027599 migraine Diseases 0.000 claims description 6
- 201000006417 multiple sclerosis Diseases 0.000 claims description 6
- 208000005298 acute pain Diseases 0.000 claims description 5
- 208000009935 visceral pain Diseases 0.000 claims description 5
- 206010002383 Angina Pectoris Diseases 0.000 claims description 4
- 208000000003 Breakthrough pain Diseases 0.000 claims description 4
- 206010058019 Cancer Pain Diseases 0.000 claims description 4
- 208000006561 Cluster Headache Diseases 0.000 claims description 4
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 claims description 4
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 4
- 206010065390 Inflammatory pain Diseases 0.000 claims description 4
- 208000004404 Intractable Pain Diseases 0.000 claims description 4
- 208000007914 Labor Pain Diseases 0.000 claims description 4
- 208000008930 Low Back Pain Diseases 0.000 claims description 4
- 206010036376 Postherpetic Neuralgia Diseases 0.000 claims description 4
- 208000004550 Postoperative Pain Diseases 0.000 claims description 4
- 208000008765 Sciatica Diseases 0.000 claims description 4
- 125000002723 alicyclic group Chemical group 0.000 claims description 4
- 208000018912 cluster headache syndrome Diseases 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 210000005036 nerve Anatomy 0.000 claims description 4
- 230000001272 neurogenic effect Effects 0.000 claims description 4
- 230000002981 neuropathic effect Effects 0.000 claims description 4
- 201000008482 osteoarthritis Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 125000006413 ring segment Chemical group 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 206010044652 trigeminal neuralgia Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 208000006820 Arthralgia Diseases 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims description 2
- 208000009137 Behcet syndrome Diseases 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 206010006002 Bone pain Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 2
- 206010064012 Central pain syndrome Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 206010008479 Chest Pain Diseases 0.000 claims description 2
- 208000020401 Depressive disease Diseases 0.000 claims description 2
- 201000009273 Endometriosis Diseases 0.000 claims description 2
- 208000024720 Fabry Disease Diseases 0.000 claims description 2
- 206010016059 Facial pain Diseases 0.000 claims description 2
- 208000001640 Fibromyalgia Diseases 0.000 claims description 2
- 208000007514 Herpes zoster Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- 206010021639 Incontinence Diseases 0.000 claims description 2
- 208000035945 Labour pain Diseases 0.000 claims description 2
- 206010024229 Leprosy Diseases 0.000 claims description 2
- 206010026749 Mania Diseases 0.000 claims description 2
- 208000016285 Movement disease Diseases 0.000 claims description 2
- 206010028289 Muscle atrophy Diseases 0.000 claims description 2
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 2
- 208000030858 Myofascial Pain Syndromes Diseases 0.000 claims description 2
- 206010061533 Myotonia Diseases 0.000 claims description 2
- 208000005890 Neuroma Diseases 0.000 claims description 2
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 2
- 206010031009 Oral pain Diseases 0.000 claims description 2
- 206010033557 Palpitations Diseases 0.000 claims description 2
- 206010033645 Pancreatitis Diseases 0.000 claims description 2
- 206010033647 Pancreatitis acute Diseases 0.000 claims description 2
- 208000000450 Pelvic Pain Diseases 0.000 claims description 2
- 208000010886 Peripheral nerve injury Diseases 0.000 claims description 2
- 208000004983 Phantom Limb Diseases 0.000 claims description 2
- 206010056238 Phantom pain Diseases 0.000 claims description 2
- 206010037779 Radiculopathy Diseases 0.000 claims description 2
- 206010038419 Renal colic Diseases 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims description 2
- 208000000491 Tendinopathy Diseases 0.000 claims description 2
- 206010043255 Tendonitis Diseases 0.000 claims description 2
- 206010043269 Tension headache Diseases 0.000 claims description 2
- 208000008548 Tension-Type Headache Diseases 0.000 claims description 2
- 208000009205 Tinnitus Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 208000025609 Urogenital disease Diseases 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims description 2
- 210000001015 abdomen Anatomy 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 201000003229 acute pancreatitis Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 206010003119 arrhythmia Diseases 0.000 claims description 2
- 230000006793 arrhythmia Effects 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 208000034757 axonal type 2FF Charcot-Marie-Tooth disease Diseases 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 230000005176 gastrointestinal motility Effects 0.000 claims description 2
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 208000014674 injury Diseases 0.000 claims description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 201000010901 lateral sclerosis Diseases 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 208000005264 motor neuron disease Diseases 0.000 claims description 2
- 230000020763 muscle atrophy Effects 0.000 claims description 2
- 201000000585 muscular atrophy Diseases 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 208000015706 neuroendocrine disease Diseases 0.000 claims description 2
- 201000001119 neuropathy Diseases 0.000 claims description 2
- 230000007823 neuropathy Effects 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 208000001297 phlebitis Diseases 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 201000007094 prostatitis Diseases 0.000 claims description 2
- 238000001959 radiotherapy Methods 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 201000009890 sinusitis Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 208000005198 spinal stenosis Diseases 0.000 claims description 2
- 230000007863 steatosis Effects 0.000 claims description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 2
- 230000009885 systemic effect Effects 0.000 claims description 2
- 201000004415 tendinitis Diseases 0.000 claims description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 231100000886 tinnitus Toxicity 0.000 claims description 2
- 208000004371 toothache Diseases 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 208000026533 urinary bladder disease Diseases 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 206010019909 Hernia Diseases 0.000 claims 1
- 206010037596 Pyelonephritis Diseases 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 208000003243 intestinal obstruction Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 4
- 0 CC1(*)C=NN=CN=C1 Chemical compound CC1(*)C=NN=CN=C1 0.000 description 3
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97925807P | 2007-10-11 | 2007-10-11 | |
| US60/979,258 | 2007-10-11 | ||
| PCT/US2008/079542 WO2009049180A2 (en) | 2007-10-11 | 2008-10-10 | Heteroaryl amides useful as inhibitors of voltage-gated sodium channels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011500598A JP2011500598A (ja) | 2011-01-06 |
| JP2011500598A5 true JP2011500598A5 (cg-RX-API-DMAC7.html) | 2012-11-15 |
| JP5555169B2 JP5555169B2 (ja) | 2014-07-23 |
Family
ID=40429979
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010529091A Active JP5555169B2 (ja) | 2007-10-11 | 2008-10-10 | 電位開口型ナトリウムチャネルの阻害剤として有用なヘテロアリールアミド |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8519137B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2227453B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5555169B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN101883760A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2008310660A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2701946A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010003866A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ584475A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009049180A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5855095B2 (ja) | 2010-06-07 | 2016-02-09 | ノボメディックス, エルエルシーNovomedix, Llc | フラニル化合物およびその使用 |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| US9212209B2 (en) | 2012-07-13 | 2015-12-15 | Indiana University Research And Technology Corporation | Screening methods for spinal muscular atrophy |
| AR095192A1 (es) | 2013-01-31 | 2015-09-30 | Vertex Pharma | Quinolina y quinazolinamidas como modulares de canales de sodio |
| AR094667A1 (es) | 2013-01-31 | 2015-08-19 | Vertex Pharma | Piridonamidas como moduladores de canales de sodio |
| US9108903B2 (en) | 2013-01-31 | 2015-08-18 | Vertex Pharmaceuticals Incorporated | Amides as modulators of sodium channels |
| CA2918365C (en) | 2013-07-19 | 2021-09-07 | Vertex Pharmaceuticals Incorporated | Sulfonamides as modulators of sodium channels |
| UA121379C2 (uk) | 2013-12-13 | 2020-05-25 | Вертекс Фармасьютикалз Інкорпорейтед | Проліки піридонамідів, застосовувані як модулятори натрієвих каналів |
| US10865181B2 (en) | 2014-11-05 | 2020-12-15 | University Of Kansas | Small molecule inhibitors of the mitochondrial permeability transition pore (mtPTP) |
| BR112017017182A2 (pt) | 2015-02-12 | 2018-04-03 | Univ Southern California | composto para tratamento de doenças ou condições por inibição da atividade ou expressão de gh, ghr, stat5, igf-1 e/ou socs e de proteínas reguladas por gh, ghr, stat5, socs, igf-1 e insulina humanos; compostos para tratamento de doenças ou condições por inibição da atividade ou expressão de gh, ghr, stat5, socs, igf-1 e insulina e de proteínas reguladas por gh, ghr, stat5, socs, igf-1 e insulina humanos; método para tratamento de doenças ou condições com alterações em genes da sinalização relacionados com gh, ghr, stat5 e socs humanos; e método para tratamento de doenças ou condições causadas por atividade de hormônios do crescimento |
| JP7104070B2 (ja) | 2017-05-16 | 2022-07-20 | バーテックス ファーマシューティカルズ インコーポレイテッド | ナトリウムチャネルの調節因子としての重水素化ピリドンアミドおよびそのプロドラッグ |
| ES3008911T3 (en) | 2017-07-11 | 2025-03-25 | Vertex Pharma | Carboxamides as modulators of sodium channels |
| CN108863970A (zh) | 2017-08-14 | 2018-11-23 | 四川省中医药转化医学中心 | 新化合物及其在治疗炎症或炎症相关疾病方面的应用 |
| US20190343817A1 (en) | 2018-02-12 | 2019-11-14 | Vertex Pharmaceuticals Incorporated | Method of treating pain |
| CA3105657A1 (en) * | 2018-07-09 | 2020-01-16 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting nav1.8 |
| CN112689629B (zh) * | 2018-07-09 | 2024-04-23 | 利伯研究所公司 | 用于抑制Nav1.8的哒嗪化合物 |
| WO2020047312A1 (en) * | 2018-08-31 | 2020-03-05 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors |
| JOP20210097A1 (ar) | 2018-11-02 | 2023-01-30 | Merck Sharp & Dohme | مركبات 2-أمينو-n-أريل غير متجانس-نيكوتيناميد كمثبطات nav1.8 |
| EP3873468A4 (en) * | 2018-11-02 | 2022-10-26 | Merck Sharp & Dohme LLC | 2-AMINO-N-PHENYL-NICOTINAMIDES AS NAV1.8 INHIBITORS |
| WO2020146612A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| US12441703B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| WO2020199683A1 (zh) * | 2019-04-04 | 2020-10-08 | 上海海雁医药科技有限公司 | 氮杂环取代的磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
| CN112390745B (zh) * | 2019-08-19 | 2022-10-21 | 江苏恒瑞医药股份有限公司 | 吡啶烟酰胺类衍生物、其制备方法及其在医药上的应用 |
| SI4069691T1 (sl) | 2019-12-06 | 2025-02-28 | Vertex Pharmaceuticals Incorporated | Substituirani tetrahidrofurani kot modulatorji natrijevih kanalčkov |
| MX2022015581A (es) | 2020-06-17 | 2023-01-24 | Merck Sharp & Dohme Llc | 2-oxoimidazolidin-4-carboxamidas como inhibidores de nav1.8. |
| BR112023023239A2 (pt) | 2021-05-07 | 2024-01-23 | Merck Sharp & Dohme Llc | Carboxamidas de cicloalquil 3-oxopiperazina e carboxamidas de cicloheteroalquil 3-oxopiperazina como inibidores de nav1.8 |
| EP4347031B1 (en) | 2021-06-04 | 2025-10-29 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
| US11999699B2 (en) | 2021-06-15 | 2024-06-04 | Grünenthal GmbH | Substituted pyrazole amides |
| EP4472966A2 (en) * | 2022-02-04 | 2024-12-11 | Latigo Biotherapeutics, Inc. | Sodium channel blocking compounds, derivatives thereof, and methods of their use |
| CN116655497B (zh) * | 2022-02-25 | 2025-06-03 | 中国科学院上海药物研究所 | 脒类衍生化合物及其制备方法和用途 |
| CN116789644B (zh) * | 2022-03-17 | 2025-11-11 | 中国科学院上海药物研究所 | 酰胺类化合物及其制备方法和用途 |
| CR20240513A (es) | 2022-04-22 | 2025-04-30 | Vertex Pharma | Compuestos de heteroarilo para el tratamiento del dolor |
| EP4385980A1 (en) | 2022-12-14 | 2024-06-19 | Grünenthal GmbH | Indazoles as inhibitors of nav1.8 |
| EP4385979A1 (en) | 2022-12-14 | 2024-06-19 | Grünenthal GmbH | Multicyclic inhibitors of nav1.8 |
| AR131345A1 (es) | 2022-12-14 | 2025-03-12 | Gruenenthal Gmbh | SULFOXIMINAS COMO INHIBIDORES DE NaV1.8 |
| EP4385984A1 (en) | 2022-12-14 | 2024-06-19 | Grünenthal GmbH | Pyridine-n-oxides as inhibitors of nav1.8 |
| CN119285621B (zh) * | 2024-12-13 | 2025-07-18 | 嘉兴安帝康生物科技有限公司 | 作为钠通道调节剂的四氢呋喃甲酰胺类化合物及其在医药上的应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL105345C (cg-RX-API-DMAC7.html) * | 1957-05-29 | |||
| EP0008367B1 (de) * | 1978-07-20 | 1983-08-10 | BASF Aktiengesellschaft | N-Arylsulfonylpyrrole, ihre Herstellung und diese enthaltende therapeutische Mittel |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| HRP20010206A2 (en) * | 1998-08-20 | 2004-02-29 | Agouron Pharma | NON-PEPTIDE GnRH AGENTS, METHODS AND INTERMEDIATES FOR THEIR PREPARATION |
| JP2002529455A (ja) * | 1998-11-09 | 2002-09-10 | ジェームズ・ブラック・ファウンデーション・リミテッド | ガストリンおよびコレシストキニン受容体リガンド類 |
| US6620849B2 (en) * | 2000-07-26 | 2003-09-16 | Icafen, Inc. | Potassium channel inhibitors |
| US6995162B2 (en) * | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US7105682B2 (en) * | 2001-01-12 | 2006-09-12 | Amgen Inc. | Substituted amine derivatives and methods of use |
| ES2338539T3 (es) * | 2001-11-01 | 2010-05-10 | Icagen, Inc. | Pirazolamidas para uso en el tratamiento del dolor. |
| SE0203752D0 (sv) | 2002-12-17 | 2002-12-17 | Astrazeneca Ab | New compounds |
| WO2004106324A1 (en) * | 2003-05-27 | 2004-12-09 | E.I. Dupont De Nemours And Company | Azolecarboxamide herbicides |
| CA2539227A1 (en) | 2003-08-08 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Heteroarylaminosulfonylphenyl derivatives for use as sodium or calcium channel blockers in the treatment of pain |
| NZ547109A (en) * | 2003-10-28 | 2010-03-26 | Vertex Pharma | Benzimidazoles useful as modulators of ion channels |
| CA2586870A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
| DOP2006000210A (es) * | 2005-10-04 | 2007-06-15 | Aventis Pharma Inc | Compuestos de pirimidina amida como inhibidores de pgds |
| US8163746B2 (en) * | 2006-04-19 | 2012-04-24 | Astellas Pharma Inc. | Azolecarboxamide derivative |
-
2008
- 2008-10-10 US US12/249,230 patent/US8519137B2/en active Active
- 2008-10-10 CA CA2701946A patent/CA2701946A1/en not_active Abandoned
- 2008-10-10 EP EP08838105.8A patent/EP2227453B1/en active Active
- 2008-10-10 AU AU2008310660A patent/AU2008310660A1/en not_active Abandoned
- 2008-10-10 NZ NZ584475A patent/NZ584475A/en not_active IP Right Cessation
- 2008-10-10 WO PCT/US2008/079542 patent/WO2009049180A2/en not_active Ceased
- 2008-10-10 MX MX2010003866A patent/MX2010003866A/es not_active Application Discontinuation
- 2008-10-10 JP JP2010529091A patent/JP5555169B2/ja active Active
- 2008-10-10 CN CN2008801180521A patent/CN101883760A/zh active Pending